- Home
- GHI vs PRQR Comparison
GHI vs PRQR Comparison
Compare GHI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- PRQR
- Stock Information
- Founded
- GHI 1998
- PRQR 2012
- Country
- GHI United States
- PRQR Netherlands
- Employees
- GHI N/A
- PRQR N/A
- Industry
- GHI Finance: Consumer Services
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- PRQR Health Care
- Exchange
- GHI Nasdaq
- PRQR Nasdaq
- Market Cap
- GHI 269.5M
- PRQR 163.3M
- IPO Year
- GHI N/A
- PRQR 2014
- Fundamental
- Price
- GHI $12.00
- PRQR $1.66
- Analyst Decision
- GHI Strong Buy
- PRQR Strong Buy
- Analyst Count
- GHI 4
- PRQR 7
- Target Price
- GHI $16.00
- PRQR $9.00
- AVG Volume (30 Days)
- GHI 35.3K
- PRQR 470.6K
- Earning Date
- GHI 05-07-2025
- PRQR 05-08-2025
- Dividend Yield
- GHI 12.33%
- PRQR N/A
- EPS Growth
- GHI N/A
- PRQR N/A
- EPS
- GHI 0.45
- PRQR N/A
- Revenue
- GHI $34,065,322.00
- PRQR $21,212,711.00
- Revenue This Year
- GHI $224.76
- PRQR $2.87
- Revenue Next Year
- GHI $5.50
- PRQR N/A
- P/E Ratio
- GHI $26.81
- PRQR N/A
- Revenue Growth
- GHI N/A
- PRQR 85.91
- 52 Week Low
- GHI $10.12
- PRQR $1.07
- 52 Week High
- GHI $15.31
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- GHI 57.03
- PRQR 52.16
- Support Level
- GHI $11.26
- PRQR $1.66
- Resistance Level
- GHI $11.93
- PRQR $1.83
- Average True Range (ATR)
- GHI 0.33
- PRQR 0.10
- MACD
- GHI 0.06
- PRQR -0.00
- Stochastic Oscillator
- GHI 100.00
- PRQR 48.48
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.